{
  "header.languageSelect": "Select Language",
  "header.english": "English",
  "header.spanish": "Español",
  "languages": {
    "english": "English",
    "spanish": "Español"
  },
  "header": {
    "languageSelect": "Select Language",
    "english": "English",
    "spanish": "Español",
    "title": "GlobalCxCa - Cervical Cancer Prevention Scenario Tool"
  },
  "footer": {
    "centerForGlabalHealth": "Center for Global Health",
    "atTheNationalCancerInstitute": "at the National Cancer Institute",
    "contactInformation": "CONTACT INFORMATION",
    "contactUs": "Contact Us",
    "policies": "POLICIES",
    "accessibility": "Accessibility",
    "disclaimer": "Disclaimer",
    "FOIA": "FOIA",
    "HHSVulnerabilityDisclosure": "HHS Vulnerability Disclosure",
    "moreInformation": "MORE INFORMATION",
    "usDepartmentOfHealthAndHumanServices": "U.S. Department of Health and Human Services",
    "nationalInstitutesOfHealth": "National Institutes of Health",
    "nationalCancerInstitude": "National Cancer Institute",
    "usaGov": "USA.gov",
    "nihSlogan": "NIH ... Turning Discovery Into Health "
  },
  "navbar": {
    "home": "Home",
    "runScenario": "Run Scenario",
    "runScenarioResults": "Run Scenario - Results",
    "compareScenarios": "Compare Scenarios",
    "about": "About"
  },
  "home": {
    "introdution": "Explore epidemiological outcomes for target populations with our screening impact assessment tool."
  },
  "general": {
    "﻿Key": "English",
    "welcome": "Welcome",
    "enterValue0t100HelpText": "Enter a value between 0 and 100.",
    "screening": "Sceening",
    "screeningTestLabel": "Screening Test",
    "triage": "Triage",
    "triageTestLabel": "Triage Test",
    "diagnosis": "Diagnosis",
    "diagnosticTestLabel": "Diagnostic Test",
    "treatment": "Treatment",
    "parameter": "Parameter",
    "lowValue": "Low Value",
    "highValue": "High Value",
    "defaultValue": "Default Value",
    "justification": "Justification",
    "sources": "Sources",
    "testName": "Test Name",
    "defaultSensitivity": "Default Sensitivity",
    "defaultSpecificity": "Default Specificity",
    "justificationText": "Justification text",
    "sourcesJustification": "Sources/justification",
    "reset": "Reset",
    "exportSVG": "Export SVG",
    "exportPNG": "Export PNG",
    "results": "Results",
    "scenarioAssumption": "Scenario Assumptions",
    "search": "Search",
    "noDataAvailable": "NO DATA AVAILABLE"
  },
  "runScenario": {
    "title": "Run Scenario",
    "fieldRequired": "All fields are required",
    "epidemiological": "Epidemiological Context",
    "epidemiologicalTitle": "Explore epidemiological outcomes for target populations with our screening impact assessment tool.",
    "numPeople": "Number of people in target population for cervical screening",
    "numPeopleInfo": "Enter targeted number of people in the population eligible for cervical screening",
    "prevelance": "Prevalence of CIN2/3 in population for cervical screening",
    "prevelanceInfo": "Enter number of women with CIN2/3 per 100 people in the population eligible for cervical screening",
    "numberWomenWithCin": "Enter number of women with CIN2/3 per 100 people in the population eligible for cervical screening",
    "strategySelectionTitle": "Strategy Selection",
    "strategyChoosen": "Please choose strategies to include in your scenario.",
    "participationTitle": "Participation in Health Services",
    "participationWarning": "Please enter the observed or anticipated participation in the cervical cancer screening program in your setting",
    "intervalofCervicalInYears": "Interval of cervical screening in years",
    "intervalInformation": "If people have one screening in a lifetime, enter 20 years. For two cervical screenings in a lifetime, enter 10 years.",
    "percentScreeningCoverage": "Percent screening coverage",
    "percentScreeningPositiveWithTriage": "Percent of screen positives with triage test",
    "percentTriagePositiveWithDiagnostic": "Percent of triage positives with diagnostic test",
    "percentDiagnosticPositiveTreated": "Percent of diagnostic test positives treated",
    "screeningAndTreatmentTitle": "Screening Strategy Characteristics",
    "screeningAndTreatmentWarning": "Please select the screening, triage and diagnostic tests and treatment modality you will use and enter an estimate of their performance characteristics.",
    "cervicalScreeningTestChosen": "Cervical screening test chosen",
    "selectTest": "Select a test",
    "screeningTestSenvitivity": "Screening test sensitivity for CIN2/3 (NIC2/3)",
    "screeningTestSpecificity": "Screening test specificity for CIN2/3 (NIC2/3)",
    "triageOrDiagnosticTestChosen": "Triage or diagnostic test chosen",
    "triageOrDiagnosticTestSensitivity": "Triage or diagnostic test sensitivity for CIN2/3 (NIC2/3)",
    "triageOrDiagnosticTestSpecificity": "Triage or diagnostic test specificity for CIN2/3 (NIC2/3)",
    "diagnosticTestChosen": "Diagnostic test chosen",
    "diagnosticTestSensitivity": "Diagnostic test sensitivity for CIN2/3 (NIC2/3)",
    "diagnosticTestSpecificity": "Diagnostic test specificity for CIN2/3 (NIC2/3)",
    "ScreenTreat": "Percent of screen positives treated",
    "ScreenDiagnosticTestTreat": "Percent of triage/diagnostic test positives treated",
    "ScreenTriageDiagnosticTestTreat": "Percent of screen positives with triage/diagnostic test",
    "percentofScreenPositivesWithDiagnostic": "Percent of screen positives with diagnostic test",
    "PapTest": "Pap test",
    "VIA": "VIA (IVAA)",
    "HPV": "HPV",
    "HPV1618": "HPV16/18",
    "impressionOfColposcopy": "Impression of colposcopy",
    "colposcopyWithBiopsy": "Colposcopy with biopsy",
    "cervicalTestChosen": "Cervical screening test chosen",
    "screeningCoverage": "Screening coverage"
  },
  "results": {
    "screenDiagnosisTreatment": "Screening → Diagnosis → Treatment",
    "screenTriageTreatment": "Screening → Triage → Treatment",
    "screenTriageDiagnosisTreatment": "Screening → Triage → Diagnosis → Treatment",
    "screenTreatment": "Screening → Treatment",
    "interventionsRequired": "Interventions Required",
    "populationWithPrecancer": "Population with Precancer",
    "populationWithoutPrecancer": "Population without Precancer",
    "precancersTreated.": "Precancers Treated",
    "annualTargets": "Annual Targets",
    "populationTargetedWithCoverageTitle": "Population targeted for screening with 100% coverage",
    "populationTargetedWithoutPrecancer": "Population targeted for screening without Precancer",
    "populationTargetedWithPrecancer": "Population targeted for screening with Precancer",
    "impactOnCervicalPrecancerTitle": "Impact on Cervical Precancer and Impact on the Population Targeted for Screening",
    "percentPrecancersTreated": "Percent precancers treated",
    "percentPolulationTargetedOverTreated": "Percent of population targeted for screening without precancer and possibly over-treated",
    "missedPrecancersTitle": "Missed Precancers",
    "totalPrecancersMissed": "Total precancers missed (% of all precancers)",
    "sourcesMissedPrecancers": "Sources of missed precancers (% missed precancers)",
    "didNotHaveScreeningTest": "Did not have screening test",
    "sensitivityOfScreeningTest": "Sensitivity of screening test",
    "lossAtTriageTest": "Loss at triage test",
    "sensitivityOfTriageTest": "Sensitivity of triage test",
    "lossAtTriageDiagnosticTest": "Loss at triage/diagnostic test",
    "sensitivityOfTriageDiagnosticTest": "Sensitivity of triage/diagnostic test",
    "lossAtDiagnosis": "Loss at diagnosis",
    "sensitivityOfDiagnosticTest": "Sensitivity of diagnostic test",
    "lossAtTreatment": "Loss at treatment",
    "AnnualImpactOnResourcesTitle": "Annual Impact on Resources",
    "totalRequiringScreeningTest": "Total requiring screening test",
    "totalRequiringTriageDiagnosticTest": "Total requiring triage/diagnostic test",
    "totalRequiringDiagnosticTest": "Total requiring diagnostic test",
    "totalRequiringTreatment": "Total requiring treatment",
    "saveScenario": "Save scenario",
    "exportResultsToPDF": "Export Results to PDF",
    "exportResultsToExcel": "Export Results to Excel"
  },
  "compareScenarios": {
    "uploadScenariosInfo": "Upload up to {{limit}} scenarios for comparison. Files must be of the “.scenario” file format. Click the title of the scenario to rename it.",
    "addScenario": "Add Scenario",
    "asssumptions": "Assumptions"
  },
  "about": {
    "title": "Description and sources for scenario parameters",
    "prevalenceJustitication": "Population-based prevalence studies suggest 1-3% prevalence, depending upon previous screening history and immunocompetency challenges in the population.",
    "prevalenceSources0": "Zhao FH, Lewkowitz AK, Hu SY, Chen F, Li LY, Zhang QM, Wu RF, Li CQ, Wei LH, Xu AD, Zhang WH, Pan QJ, Zhang X, Belinson JL, Sellors JW, Smith JS, Qiao YL, Franceschi S. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer. 2012 Dec 15;131(12):2929-38. doi: 10.1002/ijc.27571. Epub 2012 Apr 24. PMID: 22488743; PMCID: PMC3435460.",
    "prevalenceSources1": "Ting J, Kruzikas DT, Smith JS. A global review of age-specific and overall prevalence of cervical lesions. Int J Gynecol Cancer. 2010 Oct;20(7):1244-9. doi: 10.1111/igc.0b013e3181f16c5f. PMID: 21495248.",
    "prevalenceSources2": "Vesco KK et al. Screening for Cervical Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 May. Report No.: 11-05156-EF-1. PMID: 22132428.",
    "prevalenceSources3": "Web Annex A. Syntheses of evidence. In: WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.",
    "intervalofCervicalInYearsJustification": "Cervical cancer screening guidelines do not recommend screening more frequently than every 3 years. Typically screening intervals range from every 3 or 5 years to every 10 years, depending upon test sensitivity and program success with completion of follow-up. When considering a once-in-a-lifetime screening approach, enter the value 40 and a twice-in-a-lifetime approach should enter the value 20.",
    "percentScreeningCoverageJustification": " This metric refers to the percent of the population that you aim to reach over the course of their lifetime. Screening coverage varies widely by country, geographic region, resource setting, and population.",
    "percentScreeningPositiveTriageDiagnosticsJustification": "This metric refers to the percent of those with an abnormal result that will receive the subsequent triage or diagnostic test. Follow-up rates vary widely between 25-99%, depending on resources and contexts.",
    "percentScreeningPositiveTriageDiagnosticsSource": "Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, Poljak M, Murillo R, Broutet N, Riley LM, de Sanjose S. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. Lancet Glob Health. 2022 Aug;10(8):e1115-e1127. doi: 10.1016/S2214-109X(22)00241-8. PMID: 35839811; PMCID: PMC9296658.",
    "percentTriageDiagnosticTestPositivesJustification": "This metric refers to the percent of those with an abnormal result that will receive treatment. Follow-up rates vary widely between 25-99%, depending on resources and contexts.",
    "percentScreeningPositivesTriageJustification": " This metric refers to the percent of those with an abnormal result that will receive the triage/diagnostic test. Follow-up rates vary widely between 25-99%, depending on resources and contexts.",
    "percentScreeningPositivesDiagnosisJustification": "This metric refers to the percent of those with an abnormal result that will receive the triage/diagnostic test. Follow-up rates vary widely between 25-99%, depending on resources and contexts.",
    "percentDiagnosticPositivesTreatedJustification": "This metric refers to the percent of those with an abnormal result that will receive treatment. Follow-up rates vary widely between 25-99%, depending on resources and contexts.",
    "percentTriageDiagnosticTestPositivesSource": "Murillo, R., et al., Cervical cancer screening programs in Latin America and the Caribbean. Vaccine, 2008. 26 Suppl 11: p. L37-48.",
    "papTestJustification": "Pap test performance varies widely across settings. Sensitivity can range from 25-75%, with most estimates 50-70%",
    "papTestSource0": "Arbyn M, Sankaranarayanan R, Muwonge R, Keita N, Dolo A, Mbalawa CG, et al. Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer 2008; 123: 153-160.",
    "papTestSource1": "Cuzick J, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. IJC.2006;119:1095–1101.",
    "papTestSource2": "Mayrand HM, et al. Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. NEJM 2007;357:1579-1588.",
    "papTestSource3": "Almonte et al. Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. IJC 121, 706-802, 2007.",
    "papTestSource4": "Nanda K et al. Ann Intern Med 2000",
    "papTestSource5": "Web Annex A. Syntheses of evidence. In: WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. Geneva: World Health Organization",
    "viaJustification": "Estimates very wide and dependent on training and continued quality control. Global average about 65% sensitivity and 87% specificity. Estimates of test performance following a positive HPV test are similarly wide.",
    "hpvJustification": "Estimates of HPV test performance in screening programs are less variable.",
    "hpvSource1": "Cuzick J, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. IJC.2006;119:1095–1101.",
    "impressionOfColposcopyJustification": "Accuracy of colposcopic impression varies widely with significant bias. Most estimates of sensitivity are 50-80% while estimates of specificity are 70-95%.",
    "impressionOfColposcopySource": "Brown BH, Tidy JA. The diagnostic accuracy of colposcopy - A review of research methodology and impact on the outcomes of quality assurance. Eur J Obstet Gynecol Reprod Biol. 2019 Sep;240:182-186. doi: 10.1016/j.ejogrb.2019.07.003. Epub 2019 Jul 3. PMID: 31302386."
  }
}
